Here is some other vaccine news of note for the week:
> Dynavax’s hepatitis B vaccine Heplisav-B sold $1.3 million in the second quarter, up from $0.2 million in the first quarter. Release
> Emergent BioSolutions posted second-quarter revenue of $220 million, an increase of 118% year over year, thanks to sales of anthrax vaccine BioThrax and smallpox vaccine ACAM2000. Release
> Changchun Changsheng Life Sciences, embroiled in China’s latest vaccine scandal, was found to have forged production data for more than four years. Xinhua article
> The International AIDS Vaccine Initiative reached a nonexclusive license agreement with the Public Health Agency of Canada to obtain vesicular stomatitis virus vector technology for a Lassa fever vaccine currently under funding from the Coalition for Epidemic Preparedness Innovations. Release